Cardiovascular Outcomes of Vildagliptin in Patients with Type 2 Diabetes Mellitus after Acute Coronary Syndrome or Acute Ischemic Stroke

ConclusionsAmong patients with T2DM after a recent ACS or AIS, treatment with vildagliptin was not associated with increased risks of CV death, nonfatal MI, nonfatal stroke, and hospitalization for HF.This article is protected by copyright. All rights reserved.

Source: Journal of Diabetes Investigation - May 21, 2019 Category: Endocrinology Authors: Dong ‐Yi Chen, Yan‐Rong Li, Chun‐Tai Mao, Chi‐Nan Tseng, I‐Chang Hsieh, Ming‐Jui Hung, Pao‐Hsien Chu, Chao‐Hung Wang, Ming‐Shien Wen, Wen‐Jin Cherng, Tien‐Hsing Chen Tags: Original Article Source Type: research